X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3357) 3357
Book Review (712) 712
Publication (338) 338
Conference Proceeding (39) 39
Book Chapter (30) 30
Dissertation (12) 12
Government Document (3) 3
Data Set (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2293) 2293
humans (2037) 2037
alk (1715) 1715
oncology (1464) 1464
anaplastic lymphoma kinase (936) 936
female (904) 904
male (859) 859
crizotinib (852) 852
cancer (750) 750
mutation (675) 675
lung cancer (667) 667
receptor protein-tyrosine kinases - genetics (644) 644
lung neoplasms - genetics (641) 641
middle aged (633) 633
lymphomas (604) 604
adult (586) 586
immunohistochemistry (569) 569
pathology (557) 557
chemotherapy (542) 542
animals (487) 487
aged (477) 477
egfr (454) 454
lung neoplasms - drug therapy (452) 452
hemic and lymphatic diseases (440) 440
carcinoma, non-small-cell lung - genetics (433) 433
lung neoplasms - pathology (428) 428
adenocarcinoma (425) 425
expression (420) 420
identification (418) 418
lung cancer, non-small cell (409) 409
gene (406) 406
tumors (397) 397
carcinoma, non-small-cell lung - drug therapy (381) 381
receptor protein-tyrosine kinases - metabolism (373) 373
genetic aspects (351) 351
respiratory system (349) 349
cell lung-cancer (347) 347
non-small cell lung cancer (345) 345
gene rearrangement (329) 329
kinases (324) 324
protein kinase inhibitors - therapeutic use (305) 305
protein-tyrosine kinases - genetics (299) 299
cell line, tumor (295) 295
prognosis (294) 294
cell biology (291) 291
lymphoma (291) 291
mutations (290) 290
neuroblastoma (285) 285
receptor protein-tyrosine kinases (281) 281
research (280) 280
oncogene proteins, fusion - genetics (277) 277
analysis (276) 276
in situ hybridization, fluorescence (274) 274
nsclc (274) 274
carcinoma, non-small-cell lung - pathology (273) 273
receptor protein-tyrosine kinases - antagonists & inhibitors (271) 271
npm-alk (267) 267
open-label (264) 264
non-hodgkins-lymphoma (262) 262
resistance (261) 261
eml4-alk fusion gene (259) 259
mice (256) 256
hematology (255) 255
aged, 80 and over (251) 251
antineoplastic agents - therapeutic use (249) 249
adenocarcinoma - genetics (245) 245
care and treatment (244) 244
protein-tyrosine kinases - metabolism (236) 236
protein kinase inhibitors - pharmacology (228) 228
proteins (227) 227
receptor tyrosine kinase (223) 223
fusion (221) 221
metastasis (221) 221
anaplastic large cell lymphoma (218) 218
child (217) 217
protein-tyrosine kinase (207) 207
biochemistry & molecular biology (204) 204
article (203) 203
kinase (201) 201
pharmacology & pharmacy (200) 200
activating mutations (198) 198
tyrosine kinase (197) 197
inflammatory myofibroblastic tumor (194) 194
pyridines - therapeutic use (194) 194
alectinib (193) 193
ros1 (193) 193
genes (192) 192
acquired-resistance (189) 189
pyrazoles - therapeutic use (189) 189
adolescent (187) 187
tyrosine (186) 186
lung-cancer (185) 185
ceritinib (183) 183
hematology, oncology and palliative medicine (182) 182
diagnosis (180) 180
patients (179) 179
health aspects (176) 176
lymphoma, large-cell, anaplastic - pathology (170) 170
lung neoplasms - metabolism (169) 169
gefitinib (166) 166
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3318) 3318
French (32) 32
Chinese (28) 28
Japanese (15) 15
German (13) 13
Korean (6) 6
Spanish (5) 5
Russian (4) 4
Persian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biochemical Journal, ISSN 0264-6021, 12/2012, Volume 448, Issue 2, pp. 213 - 220
To investigate the range of autoinhibitory mechanisms used by TKDs (tyrosine kinase domains) from the insulin receptor family of RTKs (receptor tyrosine... 
X-ray crystallography | Insulin receptor kinase | Autoinhibition | Receptor tyrosine kinase (RTK) | Receptor tyrosine kinase-like orphan receptor 2 (Ror2) | Tropomyosin receptor kinase A (TrkA) | ALK | CRYSTAL-STRUCTURE | TYROSINE KINASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | CATALYTIC DOMAIN | autoinhibition | receptor tyrosine kinase-like orphan receptor 2 (Ror2) | ANAPLASTIC LYMPHOMA KINASE | GROWTH-FACTOR RECEPTOR | LUNG-CANCER | insulin receptor kinase | INHIBITION | receptor tyrosine kinase (RTK) | MUTATIONS | tropomyosin receptor kinase A (TrkA) | EGF RECEPTOR | Neoplasms - metabolism | Humans | Receptor, trkA - antagonists & inhibitors | Crystallography, X-Ray | Antigens, CD - genetics | Antigens, CD - metabolism | Neoplasms - genetics | Receptor, Insulin - genetics | Protein Structure, Quaternary | Antigens, CD - chemistry | Recombinant Proteins - metabolism | Amino Acid Sequence | Catalytic Domain | Recombinant Proteins - antagonists & inhibitors | Receptor Tyrosine Kinase-like Orphan Receptors - metabolism | Models, Molecular | Recombinant Proteins - chemistry | Recombinant Proteins - genetics | Receptor, Insulin - antagonists & inhibitors | Amino Acid Motifs | Receptor Tyrosine Kinase-like Orphan Receptors - antagonists & inhibitors | Receptor Tyrosine Kinase-like Orphan Receptors - chemistry | Receptor, trkA - metabolism | Receptor, Insulin - chemistry | Receptor, trkA - chemistry | Receptor, trkA - genetics | Receptor Tyrosine Kinase-like Orphan Receptors - genetics | Receptor, Insulin - metabolism | Mutation | Enzyme Activation - genetics | In Vitro Techniques | Index Medicus | ALK, anaplastic lymphoma kinase | FGFR, fibroblast growth factor receptor | Trk, tropomyosin receptor kinase | C-lobe, C-terminal lobe | EGFR, epidermal growth factor receptor | TKD, tyrosine kinase domain | DTT, dithiothreitol | NSCLC, non-small-cell lung cancer | TCEP, tris-(2-carboxyethyl)phosphine | COSMIC, Catalogue Of Somatic Mutations In Cancer | Ni-NTA, Ni2+-nitrilotriacetate | N-lobe, N-terminal lobe | RTK, receptor tyrosine kinase | CDK, cyclin-dependent kinase | IGF1R, insulin-like growth factor 1 receptor | MuSK, muscle-specific kinase | IRK, insulin receptor kinase | Ror, receptor tyrosine kinase-like orphan receptor
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2010, Volume 363, Issue 18, pp. 1693 - 1703
A small group of patients with non–small-cell lung cancer have genetic lesions that activate anaplastic lymphoma kinase (ALK). Crizotinib, an orally... 
ALK | MEDICINE, GENERAL & INTERNAL | GEFITINIB | EML4-ALK FUSION GENE | 2ND-LINE TREATMENT | PHASE-II | EGFR MUTATIONS | IDENTIFICATION | TUMORS | ACTIVATING MUTATIONS | IMMUNOHISTOCHEMISTRY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Microtubule-Associated Proteins - genetics | Humans | Middle Aged | Receptors, Growth Factor - antagonists & inhibitors | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Pyridines - adverse effects | Serine Endopeptidases - genetics | Cell Cycle Proteins - genetics | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Pyridines - administration & dosage | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Receptor Protein-Tyrosine Kinases | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Care and treatment | Lung cancer, Small cell | Genetic aspects | Diagnosis | Health aspects | Phosphotransferases | Lymphomas | Pharmaceutical industry | Lung cancer | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Nature Communications, ISSN 2041-1723, 09/2014, Volume 5, Issue 1, pp. 4846 - 4846
Human cancer genomes harbour a variety of alterations leading to the deregulation of key pathways in tumour cells. The genomic characterization of tumours has... 
ALK | RET | REARRANGEMENT | TRANSCRIPTS | PATHWAY | MULTIDISCIPLINARY SCIENCES | ETV6-NTRK3 GENE FUSION | MUTATIONS | IDENTIFICATION | EXPRESSION | DEFINE | Gene Fusion - genetics | Sequence Analysis, RNA | Neoplasms - genetics | Humans | Gene Expression Profiling | Genome, Human | Molecular Targeted Therapy | Phosphotransferases - genetics | Index Medicus
Journal Article
Nature Communications, ISSN 2041-1723, 12/2018, Volume 9, Issue 1, pp. 1126 - 15
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 2014, Volume 106, Issue 2, pp. djt378 - djt378
Journal Article
Oncogene, ISSN 0950-9232, 08/2007, Volume 26, Issue 38, pp. 5606 - 5614
The mechanisms of cell transformation mediated by the nucleophosmin (NPM)/anaplastic lymphoma kinase (ALK) tyrosine kinase are only partially understood. Here,... 
Mammalian target of rapamycin (mTOR) | Protein kinase B (PKB/Akt) | Mitogen-activated protein kinase pathway (MAPK) | Anaplastic lymphoma kinase (ALK) | MAMMALIAN TARGET | BIOCHEMISTRY & MOLECULAR BIOLOGY | anaplastic lymphoma kinase (ALK) | mammalian target of rapamycin (mTOR) | T-CELL LYMPHOMA | ANAPLASTIC LYMPHOMA | CELL BIOLOGY | mitogen-activated protein kinase pathway (MAPK) | IN-VITRO | ONCOLOGY | AMINO-ACIDS | GENETICS & HEREDITY | TRANSFORMED B-LYMPHOCYTES | NON-HODGKINS-LYMPHOMA | TUBEROUS SCLEROSIS | S6 KINASE | protein kinase B (PKB/Akt) | MEDIATED LYMPHOMAGENESIS | Immunohistochemistry | Protein Kinases - metabolism | RNA, Small Interfering - genetics | Protein Kinases - genetics | Protein-Tyrosine Kinases - metabolism | Humans | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Phosphatidylinositol 3-Kinases - metabolism | Extracellular Signal-Regulated MAP Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Extracellular Signal-Regulated MAP Kinases - genetics | Proto-Oncogene Proteins c-akt - genetics | Lymphoma, T-Cell - metabolism | Protein-Tyrosine Kinases - genetics | Transfection | Phosphatidylinositol 3-Kinases - pharmacology | Nuclear Proteins - genetics | Proto-Oncogene Proteins c-akt - metabolism | Cell Line | Cell Survival - drug effects | Nuclear Proteins - metabolism | Lymphoma, T-Cell - genetics | Receptor Protein-Tyrosine Kinases | Sirolimus - pharmacology | Blotting, Western | Phosphatidylinositol 3-Kinases - genetics | Protein Kinase Inhibitors | Animals | Mitogen-Activated Protein Kinases - antagonists & inhibitors | Signal Transduction - drug effects | Models, Biological | Lymphoma, T-Cell - pathology | Cell Line, Tumor | Mitogen-Activated Protein Kinases - genetics | Cell Proliferation - drug effects | TOR Serine-Threonine Kinases | Quinazolines - pharmacology | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Mitogen-Activated Protein Kinases - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Physiological aspects | Cellular signal transduction | Genetic aspects | Rapamycin | Dosage and administration | Research | Protein kinases | Proteins | Signal transduction | Genetics | Lymphomas | Inhibitor drugs | Cancer | Index Medicus
Journal Article
The Journal of Pathology, ISSN 0022-3417, 11/2017, Volume 243, Issue 3, pp. 307 - 319
Journal Article
Cancer Research, ISSN 0008-5472, 05/2008, Volume 68, Issue 9, pp. 3389 - 3395
Journal Article
Clinical & Experimental Immunology, ISSN 0009-9104, 10/2016, Volume 186, Issue 1, pp. 96 - 105
Journal Article
Cancer Research, ISSN 0008-5472, 12/2010, Volume 70, Issue 23, pp. 9827 - 9836
Genetic rearrangements of the anaplastic lymphoma kinase (ALK) kinase occur in 3% to 13% of non-small cell lung cancer patients and rarely coexist with KRAS or... 
NPM-ALK | GENE | ONCOLOGY | THERAPEUTIC-TARGET | SIGNALING PATHWAY | KINASE DOMAIN MUTATIONS | TYROSINE KINASE | ANAPLASTIC LYMPHOMA | SMALL-CELL-LUNG | CANCER | EGFR | Lung Neoplasms - drug therapy | Mitogen-Activated Protein Kinase Kinases - genetics | Oncogene Proteins, Fusion - metabolism | Adenocarcinoma - pathology | Paclitaxel - pharmacology | Protein-Tyrosine Kinases - metabolism | Humans | Molecular Sequence Data | Lung Neoplasms - pathology | Male | Gene Expression Profiling | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Mitogen-Activated Protein Kinase Kinases - metabolism | Protein-Tyrosine Kinases - genetics | Female | Adenocarcinoma - genetics | Antineoplastic Agents - pharmacology | HSP90 Heat-Shock Proteins - genetics | Lung Neoplasms - genetics | Amino Acid Sequence | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Mice, Transgenic | Pyrimidines - pharmacology | Adenocarcinoma - drug therapy | Receptor Protein-Tyrosine Kinases | Phosphatidylinositol 3-Kinases - genetics | Xenograft Model Antitumor Assays | Animals | Tumor Burden - drug effects | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Oncogene Proteins, Fusion - genetics | Survival Analysis | Cell Line, Tumor | HSP90 Heat-Shock Proteins - metabolism | Mice | Carboplatin - pharmacology | Cluster Analysis | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article